 |
NEWPORT NEWS, Va., June 2, 2025 /PRNewswire/ — Dilon Technologies is pleased to announce the partnership of Australian Allografts as the exclusive distributor of the Navigator 2.0™ Lymphatic Mapping System in Australia, effective immediately.
This strategic collaboration reflects Dilon Technologies’ ongoing commitment to delivering exceptional patient care through advanced medical technology. By partnering with Australian Allografts and their specialized support team, Dilon is enhancing access to the Navigator 2.0 system and reinforcing their ability to provide localized, responsive service throughout the region.
“Dilon Technologies remains steadfast in its mission to improve patient outcomes by equipping healthcare providers with precise, reliable, and user-friendly technology. The Navigator 2.0 Gamma Localization System is a critical component in breast surgery, and ensuring its continued availability is central to our dedication to clinicians and the patients they serve,” stated George Makhoul, CEO of Dilon Technologies.
In addition to the Navigator 2.0 system, Australian Allografts will also support the full portfolio of Dilon products, upholding the high standards of quality, performance, and support that healthcare providers and their patients rely on.
Logo – https://mma.prnasia.com/media2/1916512/Dilon_Technologies_Logo.jpg?p=medium600
ข่าวที่เกี่ยวข้อง
- Fair Finance Asia calls on Asian Banks and Regulators to Protect and Empower Consumers as Partners in Sustainability
- Bybit Strengthens Security Defences Against Evolving Crypto Threats, Intercepting $700 Million in Potential User Losses
- Nine Ocean Tomo Experts Named to the 2026 IAM Strategy 300 – The World’s Leading Intellectual Property Strategists
- CARsgen Therapeutics Announces 2026 Interim Results
